Activity Date: 04/08/2024
Sign in (or create a FREE account) to access this FREE session!Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on possible mechanisms for an innovative class of therapeutics that have shown promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain.
José Rey, MS, PharmD, BCPP
View biographical informationAAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Supported by Karuna, a Bristol Myers Squibb Company